Literature DB >> 19228643

Combined small cell lung carcinomas: genotypic and immunophenotypic analysis of the separate morphologic components.

Patrick L Wagner1, Naoki Kitabayashi, Yao-Tseng Chen, Anjali Saqi.   

Abstract

Combined small cell lung carcinomas (CSCLCs) are small cell lung carcinomas (SCLCs) containing discrete areas of non-small cell morphologic components, found in up to 30% of SCLCs. We assessed immunophenotypic and genotypic similarity between the distinct morphologic constituents in 7 CSCLCs. Each was stained for synaptophysin, CD56, chromogranin, bcl-2, thyroid transcription factor (TTF)-1, cytokeratin 7, and PAX-5. Loss of heterozygosity (LOH) analysis was performed using markers on 3p (2 loci), 17p (3 loci), 17q (1 locus), and 22q (2 loci). The distinct components shared an identical immunophenotype in 6 cases; all were positive for synaptophysin and CD56 in both components. LOH analysis revealed shared loss of least 1 marker in every lesion, including LOH at 22q13 (characteristic of SCLC) in 5 tumors. The individual elements constituting CSCLCs are closely related in most cases despite their distinct morphologic appearances. The prevalent expression of synaptophysin and CD56 and loss of 22q13 suggest that these tumors are biologically closer to SCLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228643     DOI: 10.1309/AJCPYNPFL56POZQY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

Review 1.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 2.  [Gastrointestinal mixed adenoneuroendocrine carcinomas. An attempt at classification of mixed cancers].

Authors:  S Reu; J Neumann; T Kirchner
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

3.  Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer.

Authors:  Chi-Fu Jeffrey Yang; Derek Y Chan; Paul J Speicher; Brian C Gulack; Xiaofei Wang; Matthew G Hartwig; Mark W Onaitis; Betty C Tong; Thomas A D'Amico; Mark F Berry; David H Harpole
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

4.  Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience.

Authors:  Chao Zhang; Haitang Yang; Heng Zhao; Baoping Lang; Xiangdong Yu; Peng Xiao; Xiao Zhang
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

5.  Correlation between histone acetylation and expression of Notch1 in human lung carcinoma and its possible role in combined small-cell lung carcinoma.

Authors:  Wael Abdo Hassan; Shin-Ichiro Takebayashi; Mohamed Osama Ali Abdalla; Kosuke Fujino; Shinji Kudoh; Yamoto Motooka; Yonosuke Sato; Yoshiki Naito; Koichi Higaki; Joeji Wakimoto; Seiji Okada; Mituyoshi Nakao; Yuichi Ishikawa; Takaaki Ito
Journal:  Lab Invest       Date:  2017-04-17       Impact factor: 5.662

6.  Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

Authors:  Xiaoliang Zhao; Justine N McCutcheon; Bhaskar Kallakury; Joeffrey J Chahine; Drew Pratt; Mark Raffeld; Yulong Chen; Changli Wang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2017-10-31       Impact factor: 15.609

7.  Combined small-cell lung carcinoma: An institutional experience.

Authors:  Audrey S Wallace; Monika Arya; Shellaine R Frazier; Steven Westgate; Zhenyu Wang; Donald Doll
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

8.  Paraneoplastic overlap syndrome in non-small squamous cell lung carcinoma.

Authors:  Romy Hoque; Lourdes DelRosso
Journal:  BMJ Case Rep       Date:  2014-03-25

9.  Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases.

Authors:  Yue-Ya Li; Chan Zhou; Deng-Xia Yang; Jing Wang; Zhu-Jun Liu; Xin-Yue Wang; Kai Li
Journal:  Cancer Biol Med       Date:  2015-06       Impact factor: 4.248

10.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Authors:  Lydia Meder; Katharina König; Luka Ozretić; Anne M Schultheis; Frank Ueckeroth; Carsten P Ade; Kerstin Albus; Diana Boehm; Ursula Rommerscheidt-Fuss; Alexandra Florin; Theresa Buhl; Wolfgang Hartmann; Jürgen Wolf; Sabine Merkelbach-Bruse; Martin Eilers; Sven Perner; Lukas C Heukamp; Reinhard Buettner
Journal:  Int J Cancer       Date:  2015-09-25       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.